|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.760 HKD | -2.06% |
|
+1.06% | +6.97% |
| 07-22 | China Resources Pharma Unit Sells 1 Billion Yuan Bonds | MT |
| 07-15 | China Resources Pharma Unit Emerges Top Bidder for Lier Chemical Stake | MT |
Company Valuation: China Resources Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,303 | 39,705 | 32,229 | 35,810 | 27,957 | 30,533 | - | - |
| Change | - | 78.03% | -18.83% | 11.11% | -21.93% | 9.21% | - | - |
| Enterprise Value (EV) 1 | 61,337 | 73,426 | 71,468 | 90,725 | 90,801 | 84,176 | 78,791 | 63,136 |
| Change | - | 19.71% | -2.67% | 26.95% | 0.08% | -7.3% | -6.4% | -19.87% |
| P/E | 5.92x | 9.58x | 7.76x | 10x | 6.12x | 6.19x | 5.79x | 5.4x |
| PBR | 0.44x | 0.8x | 0.32x | 0.34x | 0.48x | 0.48x | 0.44x | 0.38x |
| PEG | - | 1x | 44.15x | -0.7x | 0.2x | 0.76x | 0.84x | 0.76x |
| Capitalization / Revenue | 0.09x | 0.16x | 0.12x | 0.13x | 0.09x | 0.09x | 0.09x | 0.08x |
| EV / Revenue | 0.26x | 0.29x | 0.27x | 0.33x | 0.3x | 0.26x | 0.23x | 0.18x |
| EV / EBITDA | 4.83x | 4.38x | 4.65x | 5.47x | 4.73x | 4.08x | 3.69x | 3.04x |
| EV / EBIT | 6.22x | 5.39x | 5.98x | 6.98x | 6.23x | 5.08x | 4.45x | 3.39x |
| EV / FCF | 5.88x | 7.47x | 5.49x | 5.73x | 4.37x | 47.5x | 13.1x | 7.55x |
| FCF Yield | 17% | 13.4% | 18.2% | 17.5% | 22.9% | 2.11% | 7.66% | 13.3% |
| Dividend per Share 2 | 0.15 | 0.16 | 0.1669 | 0.1445 | 0.2203 | 0.2061 | 0.225 | 0.2821 |
| Rate of return | 4.23% | 2.53% | 3.25% | 2.54% | 4.95% | 4.24% | 4.63% | 5.8% |
| EPS 2 | 0.6 | 0.66 | 0.6612 | 0.5677 | 0.7268 | 0.7856 | 0.8398 | 0.8998 |
| Distribution rate | 25% | 24.2% | 25.2% | 25.5% | 30.3% | 26.2% | 26.8% | 31.4% |
| Net sales 1 | 236,806 | 254,106 | 265,229 | 275,999 | 306,131 | 325,358 | 342,036 | 359,370 |
| EBITDA 1 | 12,690 | 16,775 | 15,382 | 16,601 | 19,202 | 20,652 | 21,344 | 20,736 |
| EBIT 1 | 9,868 | 13,623 | 11,952 | 13,005 | 14,567 | 16,584 | 17,694 | 18,651 |
| Net income 1 | 3,769 | 4,147 | 4,178 | 3,589 | 4,594 | 4,835 | 5,232 | 5,645 |
| Net Debt 1 | 39,035 | 33,720 | 39,238 | 54,915 | 62,844 | 53,643 | 48,258 | 32,603 |
| Reference price 2 | 3.550 | 6.320 | 5.130 | 5.700 | 4.450 | 4.860 | 4.860 | 4.860 |
| Nbr of stocks (in thousands) | 6,282,510 | 6,282,510 | 6,282,510 | 6,282,510 | 6,282,510 | 6,282,510 | - | - |
| Announcement Date | 3/29/22 | 3/30/23 | 3/26/24 | 3/26/25 | 3/24/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 6.19x | 0.26x | 4.08x | 4.24% | 3.89B | ||
| 35.39x | 12.58x | 26.43x | 0.57% | 1,057B | ||
| 27.79x | 6.35x | 17.58x | 2.07% | 624B | ||
| 33.47x | 7.59x | 15.59x | 2.68% | 454B | ||
| 20.98x | 4.63x | 11.4x | 2.86% | 341B | ||
| 21.62x | 5.7x | 13.97x | 2.82% | 297B | ||
| 21.08x | 4.45x | 12.3x | 1.98% | 262B | ||
| 14.13x | 5.26x | 10.83x | 3.54% | 215B | ||
| 24.37x | 6.41x | 11.32x | 2.71% | 201B | ||
| -47.14x | 5.65x | 31.2x | 2.52% | 162B | ||
| Average | 15.79x | 5.89x | 15.47x | 2.6% | 361.78B | |
| Weighted average by Cap. | 24.70x | 7.88x | 18.51x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 3320 Stock
- Valuation China Resources Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
















